



CDK Targeting in Cancer Therapy

Guest Editor:

Prof. Dr. Mara A. Bonelli

Department of Medicine and
Surgery, University of Parma, Via
Gramsci, 14-43125 Parma, Italy

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

The aim of this Special Issue is to present a collection of both original studies and/or reviews, at the preclinical and clinical level, on the use of CDK inhibitors as an antitumoral strategy, to provide insights into their molecular mechanisms of action and possible resistance mechanisms.

Specific sub-topics covered may include, but are not limited to, the following:

- Evaluation of the efficacy of CDK inhibitors in solid tumor models, as a single treatment, or in combination with other target agents, immunotherapy, or chemotherapy;
- Identification of specific biomarkers of responsiveness;
- Mechanisms of resistance to CDK inhibitors which inevitably limit their clinical benefit, and strategies to overcome such resistance.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)